|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-3.95/-2.54
|
企业价值
6.79B
|
资产负债 |
每股账面净值
-7.24
|
现金流量 |
现金流量率
--
|
损益表 |
收益
9.30M
|
每股收益
0.05
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/02 14:07 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Itsproduct pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology. |